Otonomy, Inc. (OTIC) |
|
2.07 -0.01 (-0.48%)
|
07-02 20:08 |
|
Open: |
2.1 |
Pre. Close: |
2.08 |
|
High:
|
2.105 |
Low:
|
2.02 |
|
Volume:
|
95,542 |
Market Cap:
|
118(M) |
|
|
|
|
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.11 - 2.12 |
2.12 - 2.13 |
|
Low:
|
2 - 2.01 |
2.01 - 2.02 |
|
Close:
|
2.05 - 2.07 |
2.07 - 2.09 |
|
Technical analysis |
as of: 2022-07-01 4:24:14 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 2.69 One year: 3.15 |
| Support: |
Support1: 1.95 Support2: 1.74 |
| Resistance: |
Resistance1: 2.3 Resistance2: 2.69 |
| Pivot: |
1.97  |
| Moving Average: |
MA(5): 2.12 MA(20): 1.97
MA(100): 2.13 MA(250): 1.98  |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 59 %D(3): 66.2 |
| RSI: |
RSI(14): 54.2 |
| 52-week: |
High: 2.58 Low: 1.13 |
| Average Vol(K): |
3-Month: 146 (K) 10-Days: 176 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OTIC ] has closed below upper band by 30.5%. Bollinger Bands are 25.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 30 Jun 2022
Keysight's Participation in O-RAN Global PlugFest Spring 2022 Enables Ecosystem to Speed Open RAN Technology Development and Specifications Maturity - StreetInsider.com
Sat, 25 Jun 2022
Otonomy, Inc. (NASDAQ:OTIC) surges 11%; individual investors who own 32% shares profited along with institutions - Simply Wall St
Fri, 24 Jun 2022
50 medications on Mark Cuban's online pharmacy with the biggest price differences - Becker's Hospital Review
Sun, 19 Jun 2022
Off-label use of otic ciprofloxacin/dexamethasone led to hyperglycemia in infant: Case report - Medical Dialogues
Thu, 09 Jun 2022
O-RAN ALLIANCE Announces Its June 2022 Industry Summit, Progress of Its Global PlugFest Spring 2022 and a New Set of O-RAN Demos - Business Wire
Thu, 09 Jun 2022
Clinical Overview: Ciprofloxacin/Dexamethasone for Acute Otitis Media, Acute Otitis Externa - Pharmacy Times
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
57 (M) |
|
% Held by Insiders
|
3.904e+007 (%) |
|
% Held by Institutions
|
2 (%) |
|
Shares Short
|
536 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.877e+007 |
|
EPS Est Next Qtl
|
-0.69 |
|
EPS Est This Year
|
-3.24 |
|
EPS Est Next Year
|
-2.31 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-39 |
|
Return on Assets (ttm)
|
700 |
|
Return on Equity (ttm)
|
-30.8 |
|
Qtrly Rev. Growth
|
125000 |
|
Gross Profit (p.s.)
|
-58.48 |
|
Sales Per Share
|
-49.41 |
|
EBITDA (p.s.)
|
-143275 |
|
Qtrly Earnings Growth
|
-0.9 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-42 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.05 |
|
Price to Cash Flow
|
3.02 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
505340 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
